Phase II trial as new adjuvant chemotherapy regimen for capecitabine in stage II and III colorectal cancer.
Not Applicable
- Conditions
- StageII(high risk) and stageIIIa resectable colorectal cancer
- Registration Number
- JPRN-UMIN000012813
- Lead Sponsor
- Tsukasa Hotta
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1.Pregnant female 2.It may be pregnant state female 3.Past history of malignant disease 4.There is uncontrolled cerebrovascular disease 5.There was serious allergy for fluorouracl related drug 6.There was allergy due to the lack of DPD 7.There is uncontrorable infection disease 8.It is difficult to intake oral food 9.Judgementof study controlled doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence rate of side effect
- Secondary Outcome Measures
Name Time Method Disease free survival, safety, proportion of treatments completed, quality of life.